Advertisement
Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility study

January 14, 2021

Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility study

Etienne Macedo and colleagues report on a point-of-care testing program for acute kidney injury and disease in high-risk primary care patients.

Image credit: Hey Paul Studios, Flickr

Call for Papers: Global Child and Adolescent Health

We invite high quality studies addressing this topic. Submission deadline: 31 January 2021.

Read more and submit!

01/11/2021

Research Article

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Graham Jackson and colleagues study a combination induction treatment including carfilzomib for patients with transplant-eligible myeloma.

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Image credit: Sonja Schrepfer, Xiaomeng Hu, Alessia Gravina, and Dong Wang, University of California, San Francisco, Flickr

Get new content from PLOS Medicine in your inbox

Thank you! You have successfully subscribed to the PLOS Medicine newsletter.

Sorry, an error occurred while sending your subscription. Please try again later.

Try again